Brooks Laboratories Limited submitted a formal response to BSE Limited's Listing Department regarding unusual price and volume movements in the company's shares. The communication was in response to BSE's email dated October 12, 2026, bearing reference number L/SURV/ONL/PV/SJ/2026-2027/4374, which sought clarification on the price movement.
The company stated that it has disclosed all material information that could impact the company's operations and performance to the stock exchange within stipulated timeframes. This includes all necessary disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Brooks Laboratories explicitly denied having any knowledge of the reasons behind the significant changes in its share price. The company attributed the share price and volume movement to market-driven factors and stated that management is in no way connected with these price changes.
The company reaffirmed its commitment to adhering to compliance requirements under the Listing Regulations and other applicable laws. The response was signed by Prashant Rathi, who holds the positions of CEO & CFO of Brooks Laboratories Limited.
Financial Impact
No specific financial impact or quantitative figures were disclosed in this regulatory filing. The document serves as a compliance response to exchange surveillance inquiries.